ChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing
NonrulemakingNoticeFDA-2026-N-1321-0001
Comments
67
Awaiting comments
Deadline
16 days
Closes Jun 30, 2026
Net support
-48%
Support minus oppose · campaigns included
-48% excluding campaigns
Document
Details
The document's own metadata, straight from regulations.gov.
- Posted
- Apr 30, 2026
- Comment period
- Apr 30, 2026 – Jun 30, 2026
- Agency
- Food and Drug Administration (FDA)
- FR Doc
- 2026-08455
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Analyzed 62 of 67 comments
93%· analysis in progress
Stance breakdown
-48%
Net support
Support15Oppose45Other2Not yet analyzed5
Aggregates include form-letter campaigns. Excluding them, net support is -48% across organic comments.
Who commented
Breakdown by commenter type.
Individual
61
Advocacy
1
Not yet analyzed
5
Comments over time
Weekly arrivals, stacked by stance.
Posted Apr 30, 2026Deadline Jun 30, 2026
Support15Oppose45Other2
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to filter the Explorer.
Issues are identified as comment analysis progresses — nothing tagged on this document yet.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Read all 67 comments
The Explorer — every comment with stance, commenter type, and AI summaries — is part of the paid plan. $180/month per seat, 30-day money-back guarantee.